Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-01-27
2004-02-17
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06693119
ABSTRACT:
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The invention relates to the further advantageous embodiment of the German Patent Application indole-3-glyoxylamides having the reference 19814 838.0.
BACKGROUND INFORMATION
In connection with chemotherapy in the case of oncoses, the greatest problems result due to the occurrence of pharmaceutical resistance on the one hand and due to the serious side effects of these agents on the other hand.
In addition, it is known that after reaching a certain size many primary tumors prematurely tend to metastasis formation via the blood stream and lymphatic tracts. The progressive process of tumor invasion and the formation of metastases is the most frequent cause of death of the cancer patients.
There are various approaches for explaining this spread, inter alia enhanced angiogenesis, increased extracellular matrix degradation, tumor cell migration and modulation of cell adhesion. These factors can also interact but to date are only partially resolved.
The metastatic spread of a tumor is usually accompanied by poor prognoses in tumor treatment. The prerequisite for metastatic spread is the detachment of cells from the primary tumor, the migration of cells to the blood vessels, invasion into the blood vessels and invasion of the cells from the blood vessels into other tissue.
An inhibitory action of certain oncostatic agents such as tamoxoifen on the migration and invasion of cancer cells is known [J Clin Endocrinol Metab 1995 January; 80(1): 308-13].
The inhibition of tumor cell invasion by verapamil has been reported [Pigment Cell Res 1991 December; 4(5-6): 225-33.]
The influence of melantonin on invasive and metastatic properties of MCF-7 human breast cancer cells has been reported [Cancer res Oct. 1, 1998; 58(19): 4383-90].
In the published PCT Application WO 96/23506, the overcoming of pharmaceutical resistance in certain tumor pharmaceuticals was demonstrated as a result of the gene amplification of the multi-drug resistance gene (MDR gene) brought about by such oncostatic agents.
Oncostatic agents such as vincristine and Taxol furthermore have a not inconsiderable neurotoxicity, which proves disadvantageous in chemotherapy.
The object of the invention is then to widen the field of use of N-substituted indole-3-glyoxylamides and thus to enrich the available pharmaceutical wealth. The possibility of a lower, longer-lasting and better-tolerable medication for the class of substances having antitumor action described in German Patent Application 19814 838.0 should thus be opened up. In particular, the disadvantageous development of resistance, as is known of many antitumor agents, should be circumvented.
Moreover, development and spread of the tumor due to metastases should be counteracted.
According to more recent knowledge, as angiogenesis is obviously responsible for tumor growth and the development of metastases, the property of angiogenesis inhibition represents a further advantageous pharmaceutical potential, for example, in cancer therapy.
The increase in action achieved with the N-substituted indole-3-glyoxylamides should more effectively shape pharmaceutical consumption in tumor therapy. Moreover, it should be possible to shorten the period of treatment and to extend it in therapy-resistant cases. In addition, relapses and metastases should be restricted or prevented and thus the survival period of the patients additionally increased. The aim is to develop medicaments which can intervene in the process of metastatic spread.
It has surprisingly been found that the N-substituted indole-3-gloxylamides described in German Patent Application 19814 838.0, of the general formula 1 described below, which are suitable for the treatment of oncoses, further have those advantageous properties for tumor treatment which can extend their area of use.
SUMMARY OF THE INVENTION
The invention relates to the use of N-substituted indole-3-gloxylamides according to claim 1 general formula 1a for tumor treatment in particular in the case of pharmaceutical resistance and metastasizing carcinoma and for the suppression of metastasis formation, and also as angiogenesis inhibitors,
where the radicals R, R
1
, R
2
, R
3
, R
4
and Z have the following meaning:
R=hydrogen, (C
1
-C
6
)-alkyl, where the alkyl group can be mono- or polysubstituted by the phenyl ring and this phenyl ring for its part can be mono- or polysubstituted by halogen, (C
1
-C
6
)-alkyl, (C
3
-C
7
)-cycloalkyl, by carboxyl groups, carboxyl groups esterified with C
1
-C
6
-alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups and by a benzyl group which is mono- or polysubstituted in the phenyl moiety by (C
1
-C
6
)-alkyl groups, halogen atoms or trifluoromethyl groups,
R is further the benzyloxycarbonyl group (z group) and the tertiary-butoxycarbonyl radical (BOC radical), furthermore the acetyl group.
R
1
can be the phenyl ring, which is mono- or polysubstituted by (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkoxy, cyano, halogen, trifluoromethyl, hydroxyl, benzyloxy, nitro, amino, (C
1
-C
6
)-alkylamino, (C
1
-C
6
)-alkoxycarbonylamino and by the carboxyl group or by the carboxyl group esterified with C
1
-C
6
-alkanols, or can be a pyridine structure of the formula 2 and its N-oxide
and its N-oxide, where the pyridine structure is alternatively bonded to the ring carbon atoms 2, 3 and 4 and can be substituted by the substituents R
5
and R
6
. The radicals R
5
and R
6
can be identical or different and have the meaning (C
1
-C
6
)-alkyl and the meaning (C
3
-C
7
)-cycloalkyl, (C
1
-C
6
)-alkoxy, nitro, amino, hydroxyl, halogen and trifluoromethyl and further are the ethoxycarbonylamino radical and the group carboxyalkyloxy in which the alkyl group can have 1-4 C atoms.
R
1
can further be a 2- or 4-pyrimidinyl heterocycle, where the 2-pyrimidinyl ring can be mono- or polysubstituted by the methyl group, furthermore are the 2-, 3-, and 4- and 8-quinolyl structure substituted by (C
1
-C
6
)-alkyl, halogen, the nitro group, the amino group and the (C
1
-C
6
)-alkylamino radical, are a 2-, 3- and 4-quinolylmethyl group, where the ring carbons of the pyridylmethyl radical of the quinolyl group and of the quinolylmethyl radical can be substituted by (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkoxy, nitro, amino and (C
1
-C
6
)-alkoxycarbonylamino.
R
1
, in the case in which R=hydrogen, the methyl or benzyl group and the benzyloxycarbonyl radical (Z radical), the tert-butoxycarbonyl radical (BOC radical) and the acetyl group, can furthermore be the following radicals:
—CH
2
COOH; —CH(CH
3
)—COOH; —(CH
3
)
2
—CH—(CH
2
)
2
—CH—COO; H
3
C—H
2
C—CH(CH
3
)—CH(COOH)—; HO—H
2
C—CH(COOH)—; phenyl-CH
2
—CH(COOH)—; (4-imidazolyl)-CH
2
—CH—(COOH)—; HN═C(NH
2
)—NH—(CH
2
)
3
—CH(COOH)—; H
2
N—(CH
2
)
4
—CH(COOH)—; H
2
N—CO—CH
2
—CH—(COOH)—; HOOC—(CH
2
)
2
—CH(COOH)—;
R
1
, in the case in which R is hydrogen, the Z group, the BOC radical, the acetyle or the benzyl group, can furthermore be the acid radical of a natural or unnatural amino acid, e.g., the &agr;-glycyl, the &agr;-sarcosyl, the &agr;-alanyl, the &agr;-leucyl, the &agr;-isoleucyl, the &agr;-seryl, the &agr;-phenylalanyl, the &agr;-histidyl, the &agr;-prolyl, the &agr;-arginyl, the &agr;-lysyl, the &agr;-asparagyl and the &agr;-glutamyl radical, where the amino groups of the respective amino acids can be present unprotected or can be protected. A possible protective group of the amino function is the carbobenzoxy radical (Z radical) and the tert-butoxycarbonyl radical (BOC radical) as well as the acetyl group. In the case of the asparagyl and glutamyl radical claimed for R
1
, the second, unbonded carboxyl group is present as a free carboxyl group or in the form of an ester with C
1
-C
6
-alkanols, e.g., as a methyl, ethyl or as a tert-butyl ester.
Furthermore, R
1
can be the allylaminocarbonyl-2-methylprop-1-yl group. R and R
1
can further form, together with the nitrogen atom to which they are bonded, a piperazine ring of the formula III or a homopiperazine ring
Bacher Gerald
Beckers Thomas
Bruyneel Erik
Emig Peter
Engel Jürgen
Baxter Healthcare SA
Goldberg Jerome D.
Pillsbury & Winthrop LLP
LandOfFree
Indolyl-3-glyoxylic acid derivatives having therapeutically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolyl-3-glyoxylic acid derivatives having therapeutically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl-3-glyoxylic acid derivatives having therapeutically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3331092